Soleno Therapeutics Presents Clinical Data on DCCR at 2018 Foundation for Prader-Willi Research Annual Conference
08 oct. 2018 08h00 HE
|
Soleno Therapeutics
Oral presentation on DCCR’s mechanism of action in treating hyperphagia Poster presentation on DCCR’s safety profile and implications for PWS Phase III study design REDWOOD CITY, Calif., Oct. 08,...
Soleno Therapeutics Presents Clinical Data on DCCR at Late-Breaking Session of European Society for Paediatric Endocrinology
01 oct. 2018 08h00 HE
|
Soleno Therapeutics
Pharmacokinetic data supports once-daily dosingLong-term use of DCCR not associated with compromised glycemic control REDWOOD CITY, Calif., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics,...
Soleno Therapeutics to Participate in Oppenheimer Fall Summit Focused on Specialty Pharma and Rare Disease
19 sept. 2018 08h00 HE
|
Soleno Therapeutics
REDWOOD CITY, Calif., Sept. 19, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare...
Soleno Therapeutics to Present DCCR Clinical Data at Late Breaking Sessions of the European Society for Paediatric Endocrinology
17 sept. 2018 08h00 HE
|
Soleno Therapeutics
REDWOOD CITY, Calif., Sept. 17, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare...
Soleno Therapeutics Announces Expansion of Ongoing Phase III Trial of DCCR in Prader-Willi Syndrome to Include Younger Patients
06 sept. 2018 08h00 HE
|
Soleno Therapeutics
Amendment Lowers Minimum Age Inclusion Criteria to Four Years, from Eight Years, to Better Reflect Demographics of PWS Population Top-line Data from Phase III Trial Expected in First Half of 2019 ...
Soleno Therapeutics Announces Issuance of New U.S. Patent for DCCR Covering Treatment of Low Lean Body Mass in Prader-Willi Syndrome
04 sept. 2018 08h00 HE
|
Soleno Therapeutics
REDWOOD CITY, Calif., Sept. 04, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare...
Soleno Therapeutics Provides Corporate Update and Reports Second Quarter 2018 Financial Results
14 août 2018 16h05 HE
|
Soleno Therapeutics
REDWOOD CITY, Calif., Aug. 14, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the...
Soleno Therapeutics Receives Fast Track Designation from FDA for DCCR for Treatment of Prader-Willi Syndrome
30 juil. 2018 08h00 HE
|
Soleno Therapeutics
Phase III Clinical Trial Ongoing at Multiple Sites in the U.S. REDWOOD CITY, Calif., July 30, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ:SLNO), a clinical-stage...
Soleno Therapeutics To Present Corporate Update at the BIO International Convention
04 juin 2018 08h00 HE
|
Soleno Therapeutics
REDWOOD CITY, Calif., June 04, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...
Soleno Therapeutics Provides Corporate Update and Reports First Quarter 2018 Financial Results
16 mai 2018 08h00 HE
|
Soleno Therapeutics
REDWOOD CITY, Calif., May 16, 2018 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (“Soleno”) (NASDAQ:SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment...